hepatocellular carcinoma
Conditions
Interventions
None listed
Sponsors
Kitasato University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Past history, cases judged to be hepatocellular carcinoma by blood test and diagnostic imaging 2) Unresectable progressive / recurrent cases 3) Orally administrable cases; excluding cases of upper gastrointestinal dysfunction or cases of malabsorption syndrome that affect the absorption of lenvatinib 4) Cases that are 0-2 in the criteria of ECOG PS (PS must be included in medical records) 5) Cases in which one or more lesions that can be evaluated by mRECIST have been confirmed by objective data such as CT, MRI, and X-ray examination within 28 days before registration (not including the date of registration) 6) Cases without prior history of lenvatinib treatment including treatment for other carcinomas 7) Cases with sufficient organ function 8) Patients who are expected to survive at least 3 months from the date of registration 9) Cases in which consent was obtained in writing from the study subject
Exclusion criteria
Exclusion criteria: 1) Cases with a history of hypersensitivity to the ingredients of this drug 2) Patients who have been treated with other molecule-targeted drugs 3) Women who are pregnant, have a possibility of becoming pregnant, fall within 28 days postpartum, or breastfeeding. A man who wants a partner's pregnancy. 4) A case in which a mental illness or mental disorder that interferes with daily life is included and it is judged that participation in research is difficult 5) Cases judged as inappropriate for this study by the principal investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFS between 2 groups of eNOS HT1/HT1 group and Other group (HT1; the allele T at eNOS-786 and allele 4b at eNOS VNTR) | — |
Countries
Japan
Contacts
Public ContactSHINTARO AZUMA
Kitasato University Hospital Department of pharmacy
Outcome results
None listed